Akeso (HKEX: 9926.HK) is a leading biopharmaceutical company committed to the research, development, manufacturing and commercialization of the world's first or best-in-class innovative biological medicines. Founded in 2012, Akeso has built a comprehensive R&D innovation ecosystem anchored by its proprietary Tetrabody antibody technology platform, AI-powered drug R&D platform, Dual-Shield ADC technology platform, Dual-Lock T-cell engager (TCE) technology platform, Tissue-Smart siRNA/mRNA technology platform, and cell therapy technology platforms, as well as a GMP-compliant manufacturing system and a commercialization system with an advanced operation mode.
Akeso is committed to becoming a global leader in biopharmaceuticals through efficient and breakthrough innovation in R&D, developing novel therapies that are first-in-class or best-in-class, and providing better disease solutions for patients around the world.
We have been identifying strategic partners globally with high value-added potential
to cooperate in partnership, joint venture, or licensing agreement
We focuse on major disease areas such as oncology, autoimmune diseases, inflammation, metabolic diseases and neurodegenerative diseases, with robust R&D capabilities and remarkable innovative achievements
